-
JPMorgan Downgrades Canadian Solar On Valuation Concerns
Tuesday, March 27, 2018 - 11:58am | 411Read More...Canadian Solar Inc. (NASDAQ: CSIQ) stock has been on quite a run in 2018, but one Wall Street analyst said the stock could have run out of power. The Analyst JPMorgan analyst Paul Coster downgraded Canadian Solar from Neutral to Underweight and reiterated a $17 price target. The Thesis...
-
After Trump's Announcement Of Steel, Aluminum Tariffs, The Sell-Side Reacts
Friday, March 9, 2018 - 2:52pm | 541Read More...President Donald Trump unveiled plans for steel and aluminum tariffs Thursday, and several Wall Street analysts weighed in on what the tariffs could mean for the market. Voices From The Street The tariffs are good news for steel and aluminum stocks, while the exemptions will ease...
-
JPMorgan: Buy The Boston Scientific Dip
Wednesday, November 29, 2017 - 1:16pm | 514Read More...Boston Scientific Corporation (NYSE: BSX) announced Tuesday after the close a delay to earlier timelines that were established for commercialization of the LOTUS Edge Aortic Valve System in Europe and the U.S. The company had previously looked at reintroducing the product in Europe in the first...
-
Hurricane Harvey May Have Been A Tailwind For Ross Stores
Monday, September 25, 2017 - 2:30pm | 474Read More...This year’s extreme hurricane season proved disruptive to southern brick-and-mortar businesses, damaging some locations and forcing temporary closures of others. With about 7 percent of its stores in Harvey-impacted areas, Ross Stores, Inc. (NASDAQ: ROST) isn’t immune to injury ━ but it...
-
What Are The Next Steps For Amicus Therapeutics' Migalastat?
Tuesday, November 29, 2016 - 12:02pm | 279Read More...Amicus Therapeutics, Inc. (NASDAQ: FOLD) announced the path forward for U.S. regulatory approval for migalastat, including an additional trial in Fabry disease, focused on gastrointestinal (GI) symptoms. JPMorgan’s Anupama Rama maintains an Overweight rating on the company, while lowering the...
-
Growth Investments May Delay JD.Com's Path To Profits
Wednesday, August 31, 2016 - 11:35am | 364Read More...JPMorgan’s Alex Yao maintained a positive stance on the gross margin expansion outlook for JD.Com Inc(ADR) (NASDAQ: JD), while expressing caution regarding operating expense ratio outlook. Yao initiated coverage of the company with a Neutral rating and price target of $29. Positivity Tempered...
-
Bright Horizons Has Entered A Margin Inflection Point, Says JPMorgan
Monday, August 15, 2016 - 3:20pm | 415Read More...JPMorgan has upgraded Bright Horizons Family Solutions Inc (NYSE: BFAM) to Overweight from Neutral, saying the company continues to sustain multiple growth drivers and is entering a period of above-average margin expansion. "Coupled with the faster growing, higher margin Back-up care segment, we...
-
NAREIT Conference Next Week Gives JPMorgan Pause On Brixmor
Friday, June 3, 2016 - 10:53am | 203Read More...Following the conduct and accounting issues announced in early February, J.P. Morgan's Michael W. Mueller believes that the fallout risk associated with Brixmor Property Group Inc (NYSE: BRX)'s has declined considerably over the recent months. Mueller upgraded the rating on the company...
-
JPMorgan Sets $16 Price Target On Fogo De Chao
Tuesday, May 17, 2016 - 10:06am | 217Read More...Fogo De Chao Inc (NASDAQ: FOGO) reported its 1Q16 results, with the EPS slightly below the estimate. JPMorgan’s John Ivankoe downgraded the rating on the company from Overweight to Neutral, while lowering the price target from $20 to $16. 1Q Results Fogo De Chao’s 1Q16 adjusted EPS came...
-
JPMorgan Remains Neutral On Akamai Heading Into Q1 Results
Monday, April 25, 2016 - 9:26am | 293Read More...Although Akamai Technologies, Inc. (NASDAQ: AKAM) reported robust results for the previous quarter, driven by strong online holiday sales, JPMorgan’s Sterling Auty believes the March quarter numbers will reflect the current state of the company’s business better. Auty maintains a...
-
Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know
Friday, April 22, 2016 - 10:52am | 229Read More...JPMorgan’s Anupam Rama believes data from the two phase 3 trials of fostamatinib would be positive and that Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s stock could see 90-150 percent upside if that was the case. The analyst upgraded the rating on the company from Neutral to...
-
Southcross Energy Partners Hit By JP Morgan Downgrade After 10K Delay
Thursday, March 17, 2016 - 10:06am | 275Read More...J.P. Morgan’s Andrew R. Burd downgraded the rating on Southcross Energy Partners LP (NYSE: SXE) from Neutral to Underweight. The company filed it’s a FORM 12b-25 on March 16, notifying the SEC of a delay in the 10-K filing. “The filing noted that SXE does not expect to remain...
-
Reconsider Chicago Bridge & Iron, Investors
Thursday, March 3, 2016 - 11:44am | 244Read More...J.P. Morgan's Jeffrey Y. Volshteyn maintained an Overweight rating on Chicago Bridge & Iron Company N.V. (NYSE: CBI), while lowering the price target from $57 to $52. Volshteyn named the stock as J.P. Morgan's Top Pick in the E&C sector, while pointing out the attractive valuation as well...
-
JPMorgan Is Buying Alibaba, Calls This 'Elephant In The Room'
Wednesday, February 24, 2016 - 11:20am | 264Read More...JPMorgan's Vivian Hao has initiated coverage of Alibaba Group Holding Ltd (NYSE: BABA) with an Overweight rating and price target of $90. Hao believes that the stock is oversold due to concerns regarding the macro setbacks in China and the subsequent GMV deceleration. "In our view,...
-
Duke Energy's Core Is Disappointing; JPMorgan Cuts To Neutral
Friday, February 19, 2016 - 10:31am | 340Read More...JPMorgan’s Christopher Turnure has downgraded the rating on Duke Energy Corp (NYSE: DUK) from Overweight to Neutral, while lowering the price target from $82 to $81. Turnure explained that the downgrade was based on a “disappointing core business outlook,” “as growth now...












